Готові списки джерел за темами / Platinum compounds Therapeutic use

Зміст

  1. Статті в журналах
  2. Дисертації
  3. Книги
  4. Частини книг
  5. Тези доповідей конференцій

Добірка наукової літератури з теми "Platinum compounds Therapeutic use"

Автор: Grafiati
Опубліковано: 4 червня 2021
Оновлено: 29 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Platinum compounds Therapeutic use".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Platinum compounds Therapeutic use"

1

Xiao, Xiao, James Trevor Oswald, Ting Wang, Weina Zhang, and Wenliang Li. "Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery." Current Medicinal Chemistry 27, no. 18 (June 3, 2020): 3055–78. http://dx.doi.org/10.2174/0929867325666181105115849.

Повний текст джерела
Анотація:
As one of the leading and most important metal-based drugs, platinum-based pharmaceuticals are widely used in the treatment of solid malignancies. Despite significant side effects and acquired drug resistance have limited their clinical applications, platinum has shown strong inhibitory effects for a wide assortment of tumors. Drug delivery systems using emerging technologies such as liposomes, dendrimers, polymers, nanotubes and other nanocompositions, all show promise for the safe delivery of platinum-based compounds. Due to the specificity of nano-formulations; unwanted side-effects and dru
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Hassan Marouf, Bushra, and Mayyadah Mahmood Ali. "Prevention and Management of Platinum Compounds-Induced Neurotoxicity." Al-Rafidain Journal of Medical Sciences ( ISSN: 2789-3219 ) 1 (November 22, 2021): 102–9. http://dx.doi.org/10.54133/ajms.v1i.43.

Повний текст джерела
Анотація:
Oncologists considered platinum-based medicines as potent cytotoxic agents. Despite their efficacy in combination chemotherapy regimens for many solid tumors, they have many substantial side effects that limit their use. There is no known prophylactic strategy for platinum drugs-induced neurotoxicity, which limit a therapeutic dose benefit. This review highlights the etiology of platinum-drugs-induced neuropathy, and covers the preventative and therapeutic options for cancer patients. It focuses on clinical studies conducted between 2010 and 2020. Loss of functional indications such as touch,
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Makovec, Tomaz. "Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy." Radiology and Oncology 53, no. 2 (March 28, 2019): 148–58. http://dx.doi.org/10.2478/raon-2019-0018.

Повний текст джерела
Анотація:
AbstractBackgroundPlatinum-based anticancer drugs are widely used in the chemotherapy of human neoplasms. The major obstacle for the clinical use of this class of drugs is the development of resistance and toxicity. It is therefore very important to understand the chemical properties, transport and metabolic pathways and mechanism of actions of these compounds. There is a large body of evidence that therapeutic and toxic effects of platinum drugs on cells are not only a consequence of covalent adducts formation between platinum complexes and DNA but also with RNA and many proteins. These proce
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Jurgens, Sophie, Fritz E. Kuhn, and Angela Casini. "Cyclometalated Complexes of Platinum and Gold with Biological Properties: State-of-the-Art and Future Perspectives." Current Medicinal Chemistry 25, no. 4 (February 12, 2018): 437–61. http://dx.doi.org/10.2174/0929867324666170529125229.

Повний текст джерела
Анотація:
Background: The inherent problems accompanying chemotherapy necessitate the development of new anticancer approaches. The development of compounds that can disrupt cancerous cellular machinery by novel mechanisms, via interactions with proteins and non-canonical DNA structures (e.g. G-quadruplexes), as well as by alteration of the intracellular redox balance, is nowadays focus of intense research. In this context, organometallic compounds of the noble metals Pt and Au have become prominent experimental therapeutic agents. This review provides an overview of the Pt(II) and Au(III) cyclometalate
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Roszczenko, Piotr, Olga Klaudia Szewczyk, Robert Czarnomysy, Krzysztof Bielawski, and Anna Bielawska. "Biosynthesized Gold, Silver, Palladium, Platinum, Copper, and Other Transition Metal Nanoparticles." Pharmaceutics 14, no. 11 (October 25, 2022): 2286. http://dx.doi.org/10.3390/pharmaceutics14112286.

Повний текст джерела
Анотація:
Nanomedicine is a potential provider of novel therapeutic and diagnostic routes of treatment. Considering the development of multidrug resistance in pathogenic bacteria and the commonness of cancer, novel approaches are being sought for the safe and efficient synthesis of new nanoparticles, which have multifaceted applications in medicine. Unfortunately, the chemical synthesis of nanoparticles raises justified environmental concerns. A significant problem in their widespread use is also the toxicity of compounds that maintain nanoparticle stability, which significantly limits their clinical us
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Wimberger, Pauline, Barbara Klink, Konrad Gruetzmann, Julian Puppe, Daniel Klotz, Evelin Schroeck, Jan Dominik Kuhlmann, and Sarah Schott. "The activity of the conjugated antimetabolite 5-FdU-ECyd against platinum-resistant ovarian cancer." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e17077-e17077. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e17077.

Повний текст джерела
Анотація:
e17077 Background: Primary or secondary resistance to platinum-based chemotherapy is an important clinical challenge in the treatment of ovarian cancer (OC) and limits survival. Therefore, the development of innovative drugs against platinum resistance is urgently needed. Our therapeutic concept is based on the conjugation of two chemotherapeutic compounds to a monotherapeutic pro-drug, which is taken up by cancer cells and is subsequently cleaved into several active cytostatic metabolites. Our in vitro study evaluates the effects of the conjugated antimetabolite 5-FdU-ECyd, consisting of 2-de
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Maiorano, Brigida Anna, Ugo De Giorgi, Davide Ciardiello, Giovanni Schinzari, Antonio Cisternino, Giampaolo Tortora, and Evaristo Maiello. "Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day." Biomedicines 10, no. 2 (February 9, 2022): 411. http://dx.doi.org/10.3390/biomedicines10020411.

Повний текст джерела
Анотація:
Background: In advanced bladder cancer (BCa), platinum-based chemotherapy represents the first-choice treatment. In the last ten years, immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape of many solid tumors. Our review aims to summarize the main findings regarding the clinical use of ICIs in advanced BCa. Methods: We searched PubMed, Embase, and Cochrane databases, and conference abstracts from international congresses (ASCO, ESMO, ASCO GU) for clinical trials, focusing on ICIs as monotherapy and combinations in metastatic BCa. Results: 18 studies were identified. ICIs
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Marcu, Loredana G. "Gender and Sex-Related Differences in Normal Tissue Effects Induced by Platinum Compounds." Pharmaceuticals 15, no. 2 (February 20, 2022): 255. http://dx.doi.org/10.3390/ph15020255.

Повний текст джерела
Анотація:
Gender medicine in the field of oncology is an under-researched area, despite the existing evidence towards gender-dependent response to therapy and treatment-induced adverse effects. Oncological treatment aims to fulfil its main goal of achieving high tumour control by also protecting normal tissue from acute or chronic damage. Chemotherapy is an important component of cancer treatment, with a large number of drugs being currently in clinical use. Cisplatin is one of the most commonly employed chemotherapeutic agents, used either as a sole drug or in combination with other agents. Cisplatin-i
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Faraoni, Isabella, and Grazia Graziani. "Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors." Cancers 10, no. 12 (December 4, 2018): 487. http://dx.doi.org/10.3390/cancers10120487.

Повний текст джерела
Анотація:
Inhibition of poly(ADP-ribose) polymerase (PARP) activity induces synthetic lethality in mutated BRCA1/2 cancers by selectively targeting tumor cells that fail to repair DNA double strand breaks (DSBs). Clinical studies have confirmed the validity of the synthetic lethality approach and four different PARP inhibitors (PARPi; olaparib, rucaparib, niraparib and talazoparib) have been approved as monotherapies for BRCA-mutated or platinum-sensitive recurrent ovarian cancer and/or for BRCA-mutated HER2-negative metastatic breast cancer. PARPi therapeutic efficacy is higher against tumors harboring
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Krasnopolsky, Yu, D. Pylypenko, and G. Grigoryeva. "NANOMEDICINE IN ANTICANCER THERAPY." Bulletin of the National Technical University "KhPI". Series: Chemistry, Chemical Technology and Ecology 1, no. 7 (December 30, 2022): 3–13. http://dx.doi.org/10.20998/2079-0821.2022.01.

Повний текст джерела
Анотація:
The use of liposomal nanoparticles as a drug delivery system today is a promising area of modern nanopharmacology, in particular in the development of antitumor drugs. Liposomal forms of antitumor active pharmaceutical ingredients are characterized by reduced toxicity, stability, and increased antitumor activity of nanoparticle-encapsulated antitumor agent, prolonged action of the drug. Com­mercially available liposomal anticancer drugs are passively targeted drugs that accumulate in cells by passive diffusion in tumor cells due to the EPR effect of the vascular system. This review presents da
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Platinum compounds Therapeutic use"

1

Todd, Jean Ann. "Platinum(II) complexes containing 1,2- and 1,7-carborane ligands for boron neutron capture therapy." Title page, contents and abstract only, 2001. http://web4.library.adelaide.edu.au/theses/09PH/09pht634.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Du, Plessis-Stoman Debbie. "A combination of platinum anticancer drugs and mangiferin causes increased efficacy in cancer cell lines." Thesis, Nelson Mandela Metropolitan University, 2010. http://hdl.handle.net/10948/d1016160.

Повний текст джерела
Анотація:
This thesis mainly deals with some biochemical aspects regarding the efficacy of novel platinum anticancer compounds alone and in combination with mangiferin, as part of a broader study in which both chemistry and biochemistry are involved. Various novel diamine and N-S donor chelate compounds of platinum II and IV have been developed in which factors such as stereochemistry, ligand exchange rate and biocompatibility were considered as additional parameters. In the first order testing, each of these compounds was tested with reference to their “killing” potential by comparing their rate of kil
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Thomas, Donald S. "Molecular modelling and NMR studies of multinuclear platinum anticancer complexes." University of Western Australia. School of Biomedical, Biomolecular and Chemical Sciences, 2006. http://theses.library.uwa.edu.au/adt-WU2007.0009.

Повний текст джерела
Анотація:
[Truncated abstract] The trinuclear anti-cancer agent [(trans-Pt(NH3)3Cl)2{μ-trans-Pt(NH3)2(H2N(CH2)6NH2)2}]4+ (BBR3464 or 1,0,1/t,t,t) is arguably the most significant development in the field of platinum anti-cancer agents since the discovery of cisplatin as a clinical agent more than 30 years ago. Professor Nicholas Farrell of Virginia Commonwealth University was responsible for the development of 1,0,1/t,t,t and an entire class of multinuclear platinum complexes. The paradigm shift that was required in the development of these compounds is based on a simple idea. In order to increase the f
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Moniodis, Joseph John. "Studying the DNA binding of a non-covalent analogue of the trinuclear platinum anticancer agent BBR3464." University of Western Australia. School of Biomedical, Biomolecular and Chemical Sciences, 2006. http://theses.library.uwa.edu.au/adt-WU2007.0008.

Повний текст джерела
Анотація:
[Truncated abstract] The Phase II clinical candidate, [(trans-Pt(NH3)2Cl)2{μ-trans-Pt(NH3)2(H2N(CH2)6NH2)2}]4+ (BBR3464 or 1,0,1/t,t,t) shows a unique binding profile when compared to the anticancer agent cis-[Pt(NH3)2Cl2] (cisplatin) and dinuclear platinum complexes of the general formula [(trans-Pt(NH3)2Cl)2(H2N(CH2)nNH2)]2+. There is evidence that the increased efficacy of 1,0,1/t,t,t results from the presence of the charged central linker, which can alter the mode of binding to DNA. This alternate binding mode may be due to an electrostatic and hydrogen bonding association of the central p
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Zhang, Jingjing, and 张晶晶. "The anti-cancer properties of cyclometalated gold(III) complexes and organogold(III) supramolecular polymers." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/208171.

Повний текст джерела
Анотація:
Prompted by the successful clinical application of cisplatin in cancer therapy, worldwide efforts have been devoted to develop new metal-based drugs for anticancer treatment. Gold(III) complexes at first received attention as anti-cancer drug candidates because of their square-planar geometry which resembles that of platinum(II) complexes. Subsequent studies revealed that various gold(III) complexes displayed promising anti-cancer activities with different biological mechanisms. Although some achievements have been obtained in the development of anti-cancer gold(III) complexes, challenges incl
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Wong, Lai-Ming Ella, and 黃禮明. "Iron and ruthenium complexes with nitrogen and oxygen donor ligands for anti-cancer and anti-viral studies." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B3587742X.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Brynne, Niclas. "Consequences of CYP2D6 polymorphism for the disposition and dynamics of tolterodine : a novel drug in the treatment of urinary bladder overactivity /." Stockholm, 1998. http://diss.kib.ki.se/1998/91-628-3205-0/.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Tian, Songhai, and 田松海. "Proteomic and pharmacological analyses of the mechanism of actions of anticancer gold(I) complexes." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206471.

Повний текст джерела
Анотація:
Gold complexes have a long history of being used as therapeutic agents, especially in applications against immune diseases such as rheumatoid arthritis. In 1979, an oral gold(I) drug – auranofin (AuRF, brand name as Ridaura®) – was demonstrated to exhibit anticancer properties. Since then, a considerable number of gold(I) complexes have been reported to show remarkable anticancer activities, but the understanding of their mechanism of actions is limited. In the present study, AuRF and several other anticancer gold(I)-phosphine complexes including AuPEt ([Au(triethylphosphine)Cl]) were demon
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Vezmar, Marko. "Pharmacological effects of quinoline-related compounds in human tumour cells overexpressing the multidrug resistance protein (MRP)." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape16/PQDD_0003/MQ37175.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Wei, Lai, and 魏来. "Induction of LTB4 12-hydroxydehydrogenase (LTB4DH) by Radix Astragali and Radix Paeoniae Rubra: a study of theactive compounds and related biological functions." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B44683443.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Platinum compounds Therapeutic use"

1

Kuduk-Jaworska, Janina. Przeciwnowotworowo aktywne kompleksy platyny. Wrocław: Wydawn. Uniwersytetu Wrocławskiego, 1992.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

International, Congress on Neo-Adjuvant Chemotherapy (2nd 1987 Paris France). Paraplatine: Carboplatine: symposium satellite du deuxième congrès international sur la chimiothérapie néo-adjuvante Paris, 20 frévier 1988. Paris: Libbey Eurotext, 1988.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

International Symposium on Platinum Coodination Compounds in Cancer Chemotherapy (10th 2007 Verona, Italy). Platinum and other heavy metal compounds in cancer chemotherapy: Molecular mechanisms and clinical applications. New York: Humana Press, 2009.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (6th 1991 San Diego, Calif.). Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Press, 1991.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

M, Pinedo H., and Schornagel J. H, eds. Platinum and other metal coordination compounds in cancer chemotherapy 2. New York: Plenum Press, 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

International Symposium on Platinum Coodination Compounds in Cancer Chemotherapy (10th 2007 Verona, Italy). Platinum and other heavy metal compounds in cancer chemotherapy: Molecular mechanisms and clinical applications. New York: Humana Press, 2009.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Marino, Nicolini, ed. Platinum and other metal coordination compounds in cancer chemotherapy: Proceedings of the Fifth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Abano Padua, Italy, June 29-July 2, 1987. Boston: Nijhoff, 1988.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Malinowski, Jerzy. Sztuka i nowa wspólnota: Zrzeszenie Artystów Bunt, 1917-1922. Wrocław: "Wiedza o Kulturze", 1991.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

R, Kelland Lloyd, and Farrell Nicholas 1948-, eds. Platinum-based drugs in cancer therapy. Totowa, N.J: Humana Press, 2000.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

S, Tracey Alan, and Crans Debbie Catharina, eds. Vanadium compounds: Chemistry, biochemistry, and therapeutic applications. Washington, DC: American Chemical Society, 1998.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Platinum compounds Therapeutic use"

1

Bernfeld, G. J., A. J. Bird, R. I. Edwards, Hartmut Köpf, Petra Köpf-Maier, Christoph J. Raub, W. A. M. te Riele, Franz Simon, and Walter Westwood. "Medical Use of Cytostatic Platinum Compounds." In Pt Platinum, 318–38. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-662-10278-7_5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Pétain, Aurélie, Antonin Schmitt, Fabienne Thomas, Christine Chevreau, and Etienne Chatelut. "Optimising Carboplatin Dose using Patient Characteristics and Therapeutic Drug Monitoring." In Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy, 373–80. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-459-3_42.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Voegeli, R., J. Pohl, P. Hilgard, J. Engel, W. Schumacher, H. Brunner, M. Schmidt, U. Holzinger, and H. Schönenberger. "Synthesis and Therapeutic Effect of New Cis-Platinum Complexes on Experimental Tumors." In Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, 343–47. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4613-1717-3_40.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Crans, Debbie C., Mohammed Mahroof-Tahir, and Anastasios D. Keramidas. "Vanadium chemistry and biochemistry of relevance for use of vanadium compounds as antidiabetic agents." In Vanadium Compounds: Biochemical and Therapeutic Applications, 17–24. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4613-1251-2_2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Sinkó, Bálint, and Krisztina Takács-Novák. "Related Topic: Use of PAMPA and Artificial Membranes." In Skin Permeation and Disposition of Therapeutic and Cosmeceutical Compounds, 391–97. Tokyo: Springer Japan, 2017. http://dx.doi.org/10.1007/978-4-431-56526-0_35.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Altamura, A. C., and R. Curreli. "Antipsychotics in the Elderly: The Use of 'Typical� vs. 'Atypical� Compounds." In Mental Disorders in the Elderly: New Therapeutic Approaches, 125–38. Basel: KARGER, 1998. http://dx.doi.org/10.1159/000061373.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

De Pauw, Ines, Carolien Boeckx, and An Wouters. "Mechanisms of Cetuximab Resistance and How to Overcome It." In Critical Issues in Head and Neck Oncology, 21–51. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_3.

Повний текст джерела
Анотація:
AbstractDeregulated or increased signalling of the epidermal growth factor receptor (EGFR) plays an integral role in the development of various cancer types, including head and neck squamous cell carcinoma (HNSCC), making it a compelling drug target. However, after initially promising results of EGFR-targeted therapies, such as the monoclonal antibody cetuximab, it became clear that both intrinsic and acquired therapeutic resistance are major roadblocks in the field of personalised cancer treatments.In order to unravel and overcome resistance to cetuximab, at least two strategies can be adopted.Firstly, therapeutic resistance to anti-EGFR therapy may arise from mechanisms that can compensate for reduced EGFR signalling and/or mechanisms that can modulate EGFR-dependent signalling. In this chapter, we discuss which mechanisms of cetuximab resistance are already known and which ones deserve further investigation. This enhanced knowledge will guide us to rationally design and test novel combination therapies that overcome resistance to EGFR-targeting agents in cancer treatment.Secondly, an urgent need remains to develop novel targeted treatments for single-agent or combined therapy use. In this view, due to the particular mode of activation of the EGFR receptor, involving ligand-induced homo- and heterodimerization of the four HER receptors, an increased inhibition scope of HER receptors most likely results in a more potent blockade of the HER network, preventing premature emergence of resistance and leading to a more pronounced therapeutic benefit. We discuss two multitargeted compounds, being MEHD7945A (duligotuzumab) and afatinib, in this chapter.Despite the huge efforts to unravel the molecular landscape of HNSCC, the main clinically validated target remains EGFR. However, immune checkpoints, like programmed cell death protein 1 (PD-1), are gaining clinical approvals as well. We underscore the importance of adopting rational drug combinations to enhance the therapeutic effect of the EGFR-inhibitor cetuximab and highlight the ongoing search for predictive biomarkers, with the ultimate goal of delivering individualized cancer therapy to HNSCC patients.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Erbaş, Oytun, İlknur Altuntaş, Özge Çağlar, Elif Özyilmaz, Ece Sari, İlayda Üzümcü, and Kaan Erbakan. "Experimental Model of Cardiotoxicity." In Risk Factors for Cardiovascular Disease. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.101401.

Повний текст джерела
Анотація:
The occurrence of heart electrophysiology dysfunction or/and muscle damage is referred to as cardiotoxicity. The heart weakens and becomes less efficient at pumping and hence circulating blood. Cardiomyopathy can be caused by a variety of factors, including viral infections, diseases such as diabetes, ischemia, hypertension, obesity, radiation therapy, antipsychotic drugs, cytotoxic drugs, most notably chemotherapeutic agents; antitumor antibiotics, monoclonal antibodies, tyrosine kinase inhibitors, platinum-based compounds, microtubule inhibitors, vinca alkaloids, antimetabolites, proteasome inhibitors, topoisomerase inhibitors, alkylating agents, corticosteroids. This chapter focuses on the mechanisms of cardiotoxicity, animal models and transgenic methods used in studies, and the effects of therapeutic agents on cardiotoxicity.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Dwarka, Depika, Himansu Baijnath, and John Jason Mellem. "Bioactive Compounds as Therapeutic Intervention in Cancer Therapy." In Therapeutic Use of Plant Secondary Metabolites, 84–110. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815050622122010007.

Повний текст джерела
Анотація:
Neither transmittable nor communicable, painstakingly the second most fataldisease worldwide, cancer has gained the interest of scientists who are attempting withtenacity to decrypt its unknown facets, discover new diagnosis techniques, as well as tocreate improved and more efficient treatment methods. A major impediment toeffective cancer therapy is the inability to destroy the complete malignant tumourgrowth and evolution of tumour resistance. Chemotherapeutic drugs are known fortheir cell death mode of action, thereby incapacitating non-cancerous cells in theprocess. A successful anti-cancer drug should kill or debilitate cancer cells withoutcausing unnecessary damage to normal cells. Administration of natural bioactivecompounds exemplifies an alternative technique as they are associated with lowertoxicities. These bioactive molecules are effective and demonstrate great specificity asthey possibly operate as potent anti-oxidants and apoptosis inducers. Moderatingapoptosis might be helpful in managing, treating, or deterring cancer. Significantly,bioactive compounds are providing such templates. Plants have a long history in cancertreatment. More than 3000 species have been known for their anti-cancer potential.Over 60% of currently used anti-cancer agents are derived in one way or another fromhigher plants. This chapter describes the roles and advancements of the use of bioactivecompounds in the treatment of cancer.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Adeola, Henry A., Rashmi Bhardwaj, Aderonke F. Ajayi-Smith, Afsareen Bano, Tayo A. Adekiya, Michael C. Ojo, Raphael T. Aruleba, Adeniyi C. Adeola, Babatunji E. Oyinloye, and Chinedu E. Udekwu. "Bioactive Compounds as Therapeutic Intervention in Mucocutaneous Cancers." In Therapeutic Use of Plant Secondary Metabolites, 111–38. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815050622122010008.

Повний текст джерела
Анотація:
There are several beneficial effects of plant bioactive compounds in theevidence-based prevention and treatment of mucocutaneous cancers. For instance,several bioactive compounds via various antioxidant and immunomodulatorymechanisms have been shown to positively improve different diseases, includingcancer. Considering the complex, multifactorial processes that regulate genetic andcellular function in cancer development, the use of small phytochemical moleculescapable of targeting multiple carcinogenetic genes and pathways is plausible. Furthermore, the identification of molecular targets and cognate dietary bioactivemolecules in mucocutaneous cancer, using applied combinatorial chemistryapproaches, potentially presents a key complementary ancillary tool for developingrobust, physiologically bioavailable, diversity-oriented, and cost-effective therapies.These systems biology and omics-based theragnostic tools are crucial for themanagement of cancers that affect the oral mucous membranes and skin in a resourcelimitedsetting. Natural products and nutraceuticals are poised to ameliorate the burdenof mucocutaneous cancers and improve the drug discovery pipelines if state-of-the-artresearch techniques are used to elucidate their therapeutic values in the era of precisionmedicine. Hence, this review focuses on the currently available and potentialtherapeutic benefits of plant bioactive compounds in the prevention and management ofmucocutaneous cancers.
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Platinum compounds Therapeutic use"

1

Lima, Paula Marynella Alves Pereira, Douglas Cardoso Brandão, Raquel Pereira Cruz, Priscila Capelari Orsolin, Wendell Guerra, Luiz Ricardo Goulart, Robson José de Oliveira Júnior, and Thaise Gonçalves Araújo. "A NEW COPPER TERNARY COMPLEX IS A PROMISED COMPOUND FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2011.

Повний текст джерела
Анотація:
Objectives: Triple-negative breast cancer (TNBC) is a biologically aggressive tumor with poor prognosis due to the lack of effective therapeutic strategies. Although chemotherapy is widely employed, chemoresistance and severe side effects remain a challenge in controlling this breast cancer subtype. Doxorrubicin (DOX) and platinum-based drugs are commonly used in oncological regimens but with limitations. In this scenario, metallodrugs based on copper element have been emerged as novel and promised compounds, due to the presenting mechanisms of action and biodistribution different from the pla
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Suprunova, T. P., N. V. Markin, A. N. Ignatov, A. G. Solovyov, N. O. Kalinina, and M. E. Talyansky. "Use of dsRNA-based antiviral compounds to protect potato plants." In Растениеводство и луговодство. Тимирязевская сельскохозяйственная академия, 2020. http://dx.doi.org/10.26897/978-5-9675-1762-4-2020-132.

Повний текст джерела
Анотація:
One of the most important food crops in the world, the potato (Solanum tuberosum L.) is infected with many viruses, of which the y virus (Potato virus Y, PVY) is the most important economically, causing significant crop losses. Several alternative methods of dsRNA delivery have been tested, with the most promising being spray - induced gene silencing (SIGS). The results showed a high effect of preventive use of dsRNA. Treatment with the initial working concentration of dsRNA protected 100% and 65% of plants from virus propagation for 14 and 21 days, respectively, and 65% of plants were protect
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Desiderio, Mayane Freitas, Marcela Bonalumi Santos, André Mattar, Jorge Yoshinori Shida, and Luiz Henrique Gebrim. "PATHOLOGICAL COMPLETE RESPONSE IN 2,141 PATIENTS SUBMITTED TO NEOADJUVANT CHEMOTHERAPY IN A BREAST CANCER REFERENCE CENTER." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1087.

Повний текст джерела
Анотація:
Introduction: The pathologic complete response (pCR) definition after neoadjuvant chemotherapy (NAC) for breast cancer is better defined as the absence of residual invasive cancer, although it allows the presence of ductal carcinoma in situ (DCIS). In the past, the presence of positive axillary lymph node was allowed; nowadays studies have shown that any positive lymph node should be not considered as pCR. In Brazil, the proportion of advanced cases varies between 30% to 55% of patients treated by the public health system (SUS). NAC has been recommended more frequently, especially for triple n
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Marshall, Lauren, Isabel Löwstedt, Paul Gatenholm, and Joel Berry. "Prevascularized, Co-Culture Model for Breast Cancer Drug Development." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80409.

Повний текст джерела
Анотація:
The objective of this study was to create 3D engineered tissue models to accelerate identification of safe and efficacious breast cancer drug therapies. It is expected that this platform will dramatically reduce the time and costs associated with development and regulatory approval of anti-cancer therapies, currently a multi-billion dollar endeavor [1]. Existing two-dimensional (2D) in vitro and in vivo animal studies required for identification of effective cancer therapies account for much of the high costs of anti-cancer medications and health insurance premiums borne by patients, many of w
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Krasnoshtanova, Alla, and Anastasiya Bezyeva. "DETERMINATION OF THE OPTIMAL CONCENTRATIONS OF PECTIN AND CALCIUM CHLORIDE FOR THE SYNTHESIS OF CHITOSAN-PECTIN MICROPARTICLES." In GEOLINKS Conference Proceedings. Saima Consult Ltd, 2021. http://dx.doi.org/10.32008/geolinks2021/b1/v3/09.

Повний текст джерела
Анотація:
"The oral route of drug inclusion is the most convenient for the patient. In addition to ease of use, this method of drug inclusion has such advantages as non-invasiveness of inclusion, absence of complications during injection; comparative safety for the organism due to the passage of the active substance and auxiliary compounds through the gastrointestinal tract; the possibility of introducing larger doses of the drug at one time. However, despite the obvious advantages, the oral route of inclusion has a number of significant disadvantages that significantly limit its use for a number of dru
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Babarykin, Dmitry, Gaļina Smirnova, Svetlana Vasiļjeva, Anna Fedotova, Andrey Fedotov, and Natālija Basova. "Evaluation of the biological activity of sugar-free fractionated red beetroot juice." In 80th International Scientific Conference of the University of Latvia. University of Latvia, 2023. http://dx.doi.org/10.22364/iarb.2022.05.

Повний текст джерела
Анотація:
In the case of type II diabetes, the most important preventive and therapeutic effect gives a diet with a minimal amount of easily digestible carbohydrates. Vegetable juices are posi-tioned as healthy food, because of the high content of phenolic and other biologically active compounds. However, due to the high glycemic index, juices are contraindicated in obesity, and diabetes, while juices with a reduced glycemic index, are not available on the market. We have developed a technology for the fractionation of red beetroot juice based on molecular mass using ultrafiltration. The resulting fract
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Chen, Kok Hao, and Jong Hyun Choi. "DNA Oligonucleotide-Templated Nanocrystals: Synthesis and Novel Label-Free Protein Detection." In ASME 2009 International Mechanical Engineering Congress and Exposition. ASMEDC, 2009. http://dx.doi.org/10.1115/imece2009-11958.

Повний текст джерела
Анотація:
Semiconductor and magnetic nanoparticles hold unique optical and magnetic properties, and great promise for bio-imaging and therapeutic applications. As part of their stable synthesis, the nanocrystal surfaces are usually capped by long chain organic moieties such as trioctylphosphine oxide. This capping serves two purposes: it saturates dangling bonds at the exposed crystalline lattice, and it prevents irreversible aggregation by stabilizing the colloid through entropic repulsion. These nanocrystals can be rendered water-soluble by either ligand exchange or overcoating, which hampers their wi
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Platinum compounds Therapeutic use" для конкретних типів джерел:
Статті в журналах Дисертації Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії